This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Anakinra on Insulin Secretion

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2010 by Radboud University.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Radboud University Identifier:
First received: November 8, 2010
Last updated: March 23, 2012
Last verified: September 2010
November 8, 2010
March 23, 2012
January 2011
March 2012   (Final data collection date for primary outcome measure)
To determine the effect of anakinra on insulin secretion, as derived from hyperglycemic clamps . [ Time Frame: after 4 weeks of treatment with anakinra ]
Same as current
Complete list of historical versions of study NCT01285232 on Archive Site
  • To determine the effect on anakinra on insulin sensitivity. [ Time Frame: after 4 week treatment of anakinra ]
    Oral glucose tolerance test
  • Effects of anakinra on fat cell morphology and gene expression [ Time Frame: after 4 weeks of treatment with anakinra ]
Same as current
Not Provided
Not Provided
The Effect of Anakinra on Insulin Secretion
The Effect of Interleukin-1 Receptor Antagonist on Insulin Secretion in Subjects With Beta Cell Dysfunction

Rationale: Once diabetes develops, β-cell function progressively deteriorates and therapeutic approaches that prevent of delay loss of β-cell function are needed in the treatment of type 2 diabetes mellitus. Recent findings suggest that interleukin-1 (IL-1) may be involved in the progressive β-cell dysfunction in type 2 diabetes mellitus.

Objective: to determine whether blocking IL-1β by recombinant human IL-1ra (anakinra) improves beta-cell function in subjects with β-cell dysfunction.

Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
  • Glucose Intolerance
  • Impaired Insulin Secretion
  • Diabetes Mellitus Type 2
Drug: Anakinra
150 mg sc once daily during four weeks
Other Names:
  • Kineret
  • Interleukin1-receptor antagonist
  • Experimental: Anakinra
    Anakinra 150 mg/day during four weeks
    Intervention: Drug: Anakinra
  • Placebo Comparator: Placebo
    Placebo during four weeks
    Intervention: Drug: Anakinra
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
December 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Impaired glucose tolerance assessed by oral glucose tolerance test and/or impaired fasting glucose ( ≥ 5.6 mmol/L) and/or HbA1c levels of 5.7-6.4%
  • BMI >25 kg/m2
  • Age 40-70 years

Exclusion Criteria:

  • Known diabetes mellitus
  • Fasting plasma glucose ≥ 7.0 mmol/L or HbA1c ≥ 6.5%
  • Immunodeficiency or immunosuppressive treatment (including TNFα blocking agents and corticosteroids)
  • Use of anti-inflammatory drugs ( including corticosteroids and non steroidal anti-inflammatory drugs, 100 mg or less of aspirin is allowed)
  • Signs of current infection (fever, C-reactive protein >30 mmol/L, treatment with antibiotics, previous or current diagnosis of tuberculosis)
  • A history of recurrent infections
  • Pregnancy or breastfeeding (contraception of at least 3 months before inclusion is required)
  • Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range
  • Renal disease defined as MDRD < 60 ml/min/1.73m2
  • Neutropenia < 2x 109/L
  • Inability to understand the nature and extent of the trial and the procedures required.
  • Any medical condition that might interfere with the current study protocol
  • Participation in a drug trial within 60 days prior to the first dose
Sexes Eligible for Study: All
40 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Radboud University
Radboud University
Not Provided
Principal Investigator: C.J. Tack, MD, PhD, Prof. of Diabetology Radboud University
Radboud University
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP